HUE032241T2 - Eljárás és eszköz gyulladásos bélbetegség kezelésére - Google Patents

Eljárás és eszköz gyulladásos bélbetegség kezelésére Download PDF

Info

Publication number
HUE032241T2
HUE032241T2 HUE07748123A HUE07748123A HUE032241T2 HU E032241 T2 HUE032241 T2 HU E032241T2 HU E07748123 A HUE07748123 A HU E07748123A HU E07748123 A HUE07748123 A HU E07748123A HU E032241 T2 HUE032241 T2 HU E032241T2
Authority
HU
Hungary
Prior art keywords
activated
cells
column
kom
antibodies
Prior art date
Application number
HUE07748123A
Other languages
English (en)
Inventor
Magnus Thoern
Ola Winqvist
Original Assignee
Tla Targeted Immunotherapies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tla Targeted Immunotherapies Ab filed Critical Tla Targeted Immunotherapies Ab
Publication of HUE032241T2 publication Critical patent/HUE032241T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (2)

  1. ELJÁRÁS ÉS ESZKÖZ «YtJIXAßiSOS BÉLBETECsSÉG Kl' 7J3Í.SÉR£ .Vskstbílfm igésy pasink L ÉetikaferssivoiPegî, «olf'&amp;s^oiîôval »oltott amdyeti Ί dirttlooiiáfc <H. «euttotil gts»ukx;Mk kösil, :^liSÂÉ?aikiivàit-:iï»isEociták aejlfeisaíni roat keret «{leni ^[«»»«yagok vsm«»k rajrtKsbilizâlva, ahol &amp;z aktivált ív ÄtfesÄ«HiK3ilÄ»8»yagoK CD69 elfem &amp; imegnn u4;S? elleni ellernot;, agok fcviil választotuk. t»K-agy befedi! mi sksimR ismÂÉI; jp«a^k”-tiák elfem ellenanyagok « OD^b -'Ifeià elfeuauvagok kèzâl váfesKíí>É&amp;k.
  2. 2, Az K iginyp>i5i Sk^nnîi osakns tndynsk koliièibgata 20-100 e«r. Á ÁX 'Éig^pom ss«rmR 4: 1.-3. igcnyporkok irármeivike saÄi két vagy több k«ÄfeesÄlöj> komlAoáekyia, Mélpl párixuzainoss» vagy sorban kapevoii&amp;L J; -Imteáttrszme ssolgâlô b«ssÄ2% amely 1-ik igénypmkok bsnswiyifce ««sírni ονιοροί. as öÄftikiä -mábm :iétpümpk ^pmxsp^Mm. md®$ i?<vgàtà és&amp;ktM tartalmaz. é az 5. igényem sz«*aii b«^<feg^ ahol s pffip fe m imixsp s^y pMmm mim meásm^m À^ysoMsàf-àïpisIgâlô ysskbs JarkilmM két karúit J. As 5, vagy 6. lgén^o«f^|rlM.b^8#gé% φβΐ % paspl bsyifgpl êssmWÊÊk· mgéiirfA IMiködS perBrtultlkui. pumpa. t. Leiikotbrezi^re ssoipló Is-MdoíA. amely a hordozón hmaohiKaälva í»limfoctiák έ» mtua-ofo grass-kwiták kosül válaszolt aktivált feukwáák s.qtfstó«í ««atkerci elleni egy vagy több ellenanyagot ;aris!;«az. ás 1 m \ ukelk ι i k ιο^ 1 *' «. ' \ ·> κ n x~ . íj . to > év sósul íyálkSstooal, év'vagy síkú sa ekssvsk isemrofit rssnekviük ellem *.îlestanyagoîc ti í'Bbkh ólmai eHeses-yegok LS.aíI yál&amp;est''0ak. S> Á $. sgJnypoot vermit hordozó, ahol az akiivált feukoeiták a gyulladt. báivövsíMl: v«| ygy vagy lihb feíopssl«U*fe&amp;5>ől ke'kákák.
HUE07748123A 2006-05-12 2007-05-14 Eljárás és eszköz gyulladásos bélbetegség kezelésére HUE032241T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0601075 2006-05-12

Publications (1)

Publication Number Publication Date
HUE032241T2 true HUE032241T2 (hu) 2017-09-28

Family

ID=38694153

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE07748123A HUE032241T2 (hu) 2006-05-12 2007-05-14 Eljárás és eszköz gyulladásos bélbetegség kezelésére

Country Status (21)

Country Link
US (1) US8449489B2 (hu)
EP (1) EP2021025B1 (hu)
JP (1) JP5266207B2 (hu)
KR (1) KR20090007642A (hu)
CN (1) CN101443041A (hu)
AU (1) AU2007250552B2 (hu)
CA (1) CA2651883C (hu)
CY (1) CY1118286T1 (hu)
DK (1) DK2021025T3 (hu)
EA (1) EA016851B1 (hu)
ES (1) ES2603203T3 (hu)
HU (1) HUE032241T2 (hu)
IL (1) IL195001A0 (hu)
LT (1) LT2021025T (hu)
NO (1) NO20085180L (hu)
PL (1) PL2021025T3 (hu)
PT (1) PT2021025T (hu)
SG (1) SG171684A1 (hu)
SI (1) SI2021025T1 (hu)
WO (1) WO2007133147A1 (hu)
ZA (1) ZA200809429B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852581B2 (en) 2005-08-31 2014-10-07 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
PT2021025T (pt) 2006-05-12 2016-11-21 Ith Immune Therapy Holdings Ab Método e meios para tratar doença intestinal inflamatória
CN101815945A (zh) * 2007-08-02 2010-08-25 Iss免疫系统刺激股份公司 炎性肠病的诊断、分期和监测
US8877177B2 (en) 2008-09-10 2014-11-04 Ith Immune Therapy Holdings Ab Chemokine containing apheresis column and methods of use
US11285494B2 (en) 2009-08-25 2022-03-29 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US10099227B2 (en) 2009-08-25 2018-10-16 Nanoshell Company, Llc Method and apparatus for continuous removal of sub-micron sized particles in a closed loop liquid flow system
US9993590B2 (en) * 2011-01-18 2018-06-12 The Regents Of The University Of California Real-time adaptive immune system and method
US8979787B2 (en) * 2011-01-20 2015-03-17 Henry John Smith Treatment of pre-eclampsia using targeted apheresis
WO2012172343A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating primary sclerosing cholangitis
WO2012172339A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory arthritis
WO2012172336A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating inflammatory skin diseases
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
WO2012172346A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating respiratory conditions
WO2012172345A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with allergy
WO2012172337A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating cardiovascular disease
WO2012172340A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating mental disorders
WO2012172344A2 (en) * 2011-06-13 2012-12-20 Ith Immune Therapy Holdings Treating conditions associated with sepsis
ES2664836T3 (es) * 2011-06-13 2018-04-23 Tla Targeted Immunotherapies Ab Tratamiento de esclerosis múltiple
US10073097B2 (en) * 2012-11-28 2018-09-11 Charles C. Caldwell Diagnostic assays and methods of treating pneumonia, sepsis and systemic inflammatory response syndrome
EP3131559B1 (en) * 2014-04-16 2019-02-13 Genovie AB Cd8+ regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
US10758568B2 (en) 2014-04-16 2020-09-01 Genovie Ab Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
JP2022550403A (ja) * 2019-09-30 2022-12-01 ヘモチューン アーゲー 体液の体外処理のためのアセンブリ
WO2024122553A1 (ja) * 2022-12-05 2024-06-13 国立大学法人京都大学 潰瘍性大腸炎又は原発性硬化性胆管炎の治療方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS639449A (ja) 1986-07-01 1988-01-16 テルモ株式会社 血液成分分離用器具
JPH0649653B2 (ja) 1988-06-29 1994-06-29 テルモ株式会社 白血球分離材、分離器および分離方法
JPH02167071A (ja) 1988-12-19 1990-06-27 Terumo Corp 非ヒト動物由来白血球系細胞の分離材、分離器および分離方法
JPH0374A (ja) 1988-12-31 1991-01-07 Tonen Corp 白血球吸着分離材
JPH04187206A (ja) 1990-11-19 1992-07-03 Toyobo Co Ltd 白血球分離装置及び白血球分離材料の製造方法
US5728306A (en) 1994-12-23 1998-03-17 Baxter International Inc. Leukodepletion filter and method for filtering leukocytes from freshly drawn blood
DE19538641C2 (de) * 1995-10-05 2000-09-21 Privates Inst Bioserv Gmbh Patientenspezifische Immunadsorber für die extrakorporale Apherese und Verfahren für deren Herstellung
JPH1057477A (ja) 1996-08-26 1998-03-03 Asahi Medical Co Ltd 白血球除去フィルター材および白血球除去フィルター装置
JP4197545B2 (ja) 1997-12-01 2008-12-17 旭化成クラレメディカル株式会社 特異的細胞除去材料
CN100473417C (zh) * 1998-08-31 2009-04-01 安斯泰来美国有限责任公司 Cd2-结合剂调节记忆效应t-细胞的制药用途和组合物
GB0022748D0 (en) 2000-09-15 2000-11-01 Allied Therapeutics Ltd Reducing the content of cells in a biological sample
JP2003265596A (ja) 2002-03-12 2003-09-24 Asahi Kasei Corp 白血球選択吸着剤及びその評価選択方法
US6936222B2 (en) * 2002-09-13 2005-08-30 Kenneth L. Franco Methods, apparatuses, and applications for compliant membrane blood gas exchangers
US20060234210A1 (en) 2004-04-14 2006-10-19 Affinergy, Inc. Filtration device and method for removing selected materials from biological fluids
DE102005036505A1 (de) 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
WO2006125201A2 (en) 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
PT2021025T (pt) 2006-05-12 2016-11-21 Ith Immune Therapy Holdings Ab Método e meios para tratar doença intestinal inflamatória
WO2008038785A1 (fr) 2006-09-29 2008-04-03 Toray Industries, Inc. Colonne adsorbeuse de cellules

Also Published As

Publication number Publication date
CA2651883A1 (en) 2007-11-22
ZA200809429B (en) 2009-08-26
AU2007250552A1 (en) 2007-11-22
CY1118286T1 (el) 2017-06-28
WO2007133147A1 (en) 2007-11-22
AU2007250552B2 (en) 2011-07-07
KR20090007642A (ko) 2009-01-19
SI2021025T1 (sl) 2017-02-28
PT2021025T (pt) 2016-11-21
CN101443041A (zh) 2009-05-27
SG171684A1 (en) 2011-06-29
EP2021025A4 (en) 2010-08-18
JP2009536944A (ja) 2009-10-22
US20090192434A1 (en) 2009-07-30
EP2021025B1 (en) 2016-08-17
IL195001A0 (en) 2011-08-01
LT2021025T (lt) 2017-01-25
EP2021025A1 (en) 2009-02-11
NO20085180L (no) 2008-12-11
EA016851B1 (ru) 2012-08-30
CA2651883C (en) 2017-05-30
ES2603203T3 (es) 2017-02-24
EA200802086A1 (ru) 2009-06-30
DK2021025T3 (en) 2016-12-12
JP5266207B2 (ja) 2013-08-21
PL2021025T3 (pl) 2017-04-28
US8449489B2 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
HUE032241T2 (hu) Eljárás és eszköz gyulladásos bélbetegség kezelésére
RU2648354C2 (ru) Комбинированная терапия для стабильного и долговременного приживления трансплантата с использованием конкретных протоколов для т/в-клеточной деплеции
Wright et al. Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo
Hogg Neutrophil kinetics and lung injury
Karpatkin et al. Detection of splenic anti‐platelet antibody synthesis in idiopathic autoimmune thrombocytopenic purpura (ATP)
EA023912B1 (ru) Лечение воспалительных состояний
Godal et al. Evidence that the mechanism of immunological tolerance (‘central failure’) is operative in the lack of host resistance in lepromatous leprosy
Velez et al. Management of allosensitized cardiac transplant candidates
Wilton et al. The role of Fc and C3b receptors in phagocytosis by inflammatory polymorphonuclear leucocytes in man.
Kas-Deelen et al. Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: effect of acute rejection
Groen et al. Concentrations of plasma-borne extracellular particles differ between multiple sclerosis disease courses and compared to healthy controls
Hodge et al. Functional lymphocyte immunophenotypes observed in thalassaemia and haemophilia patients receiving current blood product preparations
Kuryliszyn-Moskal Comparison of blood and synovial fluid lymphocyte subsets in rheumatoid arthritis and osteoarthritis
Halff et al. Late complications with gallbladder conduit biliary reconstruction after liver transplantation
Hunt et al. The role of lymphocytes in antibody formation IV. Carriage of immunological memory by lymphocyte fractions separated by velocity sedimentation and on glass bead columns
AU2011202946A1 (en) Method and means for treating inflammatory bowel disease
JP4437335B2 (ja) ヒト未分化造血幹細胞およびその分離方法ならびに分離装置
JPS5854129B2 (ja) リンパ球分離法
Marsh et al. Studies of intestinal lymphoid tissue: X-observations on granular epithelial lymphocytes (gEL) in normal and diseased human jejunum
JPS5854128B2 (ja) リンパ球の分離方法およびその装置
Splendiani et al. Myasthenia gravis (MG) treatment with immunoadsorbent columns
JP2000139454A (ja) 細胞分離回収方法及び回収必要細胞含有液
Hiepe et al. Development of a C1q-adsorbent for the selective removal of circulating immune complexes
Belak et al. Exploring the feasibility of selective depletion of T lymphocyte subsets by whole blood immunoadsorption cytapheresis
Saleem et al. T cell reactivity to Collagen II as a possible prognostic marker in patients with rheumatoid arthritis